Skip to main content
Smart Investors Daily
IL

NASDAQ · ILMN

Illumina, Inc.

Healthcare · Medical - Diagnostics & Research

$198.00

Down-$9.01 (-4.35%)

Updated Nov 17, 2026, 3:43 AM

SID Score

6.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
20.84B
P/E ratio
30.27
Dividend yield
0.00%
52-week range
$112.65 – $309.35
Volume
1.52M
Avg. volume
1.79M

Price performance · ILMN

ILMN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

ILMN closed at $198.00 after 21 trading sessions, down 24.62% for the selected period.

Last close
$198.00
Period change
-24.62%
Period low
$198.00
Period high
$290.06
Daily close
View OHLC price history
ILMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$203.31$203.31$197.38$198.001.52M
Nov 13, 2026$209.08$209.08$202.60$207.011.23M
Nov 12, 2026$204.41$211.75$197.81$209.551.73M
Nov 11, 2026$219.97$227.71$212.74$212.931.87M
Nov 10, 2026$217.76$220.83$212.00$214.911.36M
Nov 9, 2026$216.98$222.85$211.21$220.781.86M
Nov 6, 2026$208.52$216.00$205.51$213.132.06M
Nov 5, 2026$220.25$221.475$205.00$208.004.24M
Nov 4, 2026$240.9975$244.052$224.05$226.543.04M
Nov 3, 2026$233.14$241.85$229.075$238.212.23M
Nov 2, 2026$236.01$236.01$223.33$226.582.93M
Oct 30, 2026$255.765$256.09$231.18$235.995.39M
Oct 29, 2026$286.05$293.17$283.00$290.062.04M
Oct 28, 2026$278.04$294.205$277.20$288.792.24M
Oct 27, 2026$269.42$282.18$266.20$279.471.78M
Oct 26, 2026$269.69$274.00$267.29$271.041.33M
Oct 23, 2026$264.42$271.64$264.42$269.421.26M
Oct 22, 2026$281.42$283.55$257.3101$269.402.22M
Oct 21, 2026$267.35$286.40$263.28$282.862.27M
Oct 20, 2026$264.13$271.43$260.15$267.931.58M
Oct 19, 2026$268.93$270.94$260.24$262.661.9M

Latest ILMN news

The latest Smart Investors Daily articles mentioning ILMN.

ILMN research

Overview

Company profile and research snapshot.

Company profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$115.25
Implied upside
—
Analysts
28
ILMN recent ratings
DateFirmRatingTarget
Nov 2, 2026CitigroupSell—
Oct 30, 2026Evercore ISI GroupOutperform—
Oct 30, 2026JP MorganOverweight—
Oct 19, 2026Canaccord GenuityHold—
Oct 13, 2026TD CowenHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2026

Illumina (ILMN) Stock Sees Modest Fair Value Lift As Analysts Debate Growth Outlook

Illumina’s updated valuation workpoints to a fair value of US$261.45 per share, compared with the previous US$248.90, giving you a fresh reference point for the current analyst debate. That debate is wide, with ratings now running from Sell to Buy and price targets stretching from more cautious views to the mid to high US$200s and low US$300s, as firms weigh potential upside from clinical demand and AI themes against execution and valuation risks. As you read on, you will see how to track...

Yahoo · Nov 11, 2026

Carrier Screening - Global Strategic Business Report 2026: Secure Your Share of a $7.6 Billion Market by 2032 | Features Competitive Intelligence on Illumina, Natera, BGI Genomics, and Myriad Genetics

NGS, AI, at-home testing and universal screening are expanding access, accuracy and test breadth, creating opportunities in personalized reproductive careDublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Carrier Screening - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global carrier screening market was valued at US$2.4 billion in 2025 and is projected to reach US$7.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 17.7%. Market expans

Yahoo · Nov 11, 2026

Missed Illumina's 76% Run? Here Is What Holders Saw

If Illumina sat on your watchlist instead of in your portfolio, the past year might feel like a missed shot. Investors who held Illumina over the past year are up 76.2%, including dividends. That outcome arrived alongside headlines about NovaSeq X uptake, clinical sequencing demand, and moves into multiomics. The real puzzle is what, back on 10 November 2025, could have signalled that large-scale clinical consumables adoption might matter more than China and funding worries. Narratives are...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.